FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
The CSRC has not approved U.S. IPOs since April despite a small-cap listing rebound earlier; New arbitration rules emphasize party consent, tribunal independence, and risk management in AI use; and Record-high investments in Belt and Road Initiative driven by strategic sectors.
A leading international healthcare General Counsel in the region provides an exclusive in-house perspective on the current law and practice of cross-border data transfer in China
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
Casper Sek of Jingtian & Gongcheng examines new guidance from TC260 which looks likely to become an essential component in companies’ personal information protection toolkits
Chinese manufacturers increase exports to non-U.S. markets; Revisions to the Anti-Unfair Competition Law address challenges to fair competition; China's data centers in Tibet aim to power much of China's AI
The intersection between intellectual property and artificial intelligence raises challenging and significant legal issues. Danlei Wu of Fangda Partners examines China’s first case relating to the structure and parameters of an AI model
U.S. to tighten disclosure obligations of foreign listed companies, targeting China; China to allow local investors to invest more in overseas assets under QDII; and EU issues measures to restrict Chinese medical device manufacturers from accessing public procurement contracts
Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
